<DOC>
	<DOCNO>NCT01155505</DOCNO>
	<brief_summary>This dose finding , open-label , uncontrolled , dose-escalation trial determine maximum Tolerated Dose ( MTD ) combination CC-5013 ( Lenalidomide ) paclitaxel patient advance solid tumor . Other purpose study : 1 . Define safety profile CC-5013 paclitaxel give combination 2 . Define pharmacokinetics CC-5013 paclitaxel give combination 3 . Define pharmacodynamic effect combination monitor potential biomarkers different biological activity component regimen 4 . Define optimal biological dose ( OBD ) dose recommend ( RD ) phase II study select tumor type ( breast , ovary , prostate , NSCLC ) 5 . Collect evidence antitumor activity select tumor type</brief_summary>
	<brief_title>Lenalidomide Paclitaxel Advanced Solid Tumors</brief_title>
	<detailed_description>The new immunomodulatory drug ( IMiD ) derivative thalidomide ( CC-5013 lenalidomide CC4047 pomalidomide ) endow direct antitumor activity besides indirect effect attribute antiangiogenic , antiinflammatory T-cell co-stimulatory property . Combination therapy cytotoxic agent anticancer drug could lead additive synergistic interaction support clinical development tumor type specific activity IMiDs could potential value . Combinations weekly paclitaxel could interest antiangiogenic activity , antitumor activity prostate , NSCLC , ovary , breast cancer , tumor type IMiD could clinical value either enhancement tumor specific immunity ( ovary , prostate ) inhibition Treg function ( breast , NSCLC , ovary ) .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histological/cytological diagnosis solid tumor treatment paclitaxel could indicate ( preferentially ovary , breast , prostate , NSCLC ) Documented progression tumor 3 month precede study Expected survival ≥ 3 month Age 1875 year ECOG PS 01 measurable/evaluable disease escalation phase , accord modify RECIST criterion . For patient ovarian prostatic cancer , tumor marker ( CA125 ovarian PSA prostatic ) accept evidence . Measurable/evaluable disease mandatory RD expansion phase •≤ 2 prior line chemotherapy metastatic disease . For ovarian patient reintroduction platinum relapse , initial response last &gt; 6 month consider one chemotherapy regimen Adequate contraception fertile patient Adequate hematological function define : ANC ≥ 1.5 x 109/L , platelet count ≥100 x 109/L , hemoglobin ≥ 10 g/dL . Normal PTand INR ; fibrinogen &gt; low Normal Limit ( LNL ) Adequate renal function , define : creatinine ≤ 1.5 x UNL Adequate hepatobiliary function , define follow baseline liver function test : total serum bilirubin within upper normal limit ( UNL ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤2.5xUNL ≤ 5xUNL case liver metastasis ; alkaline phosphatase ( AP ) ≤ 2.5xUNL . If total alkaline phosphatase ( AP ) &gt; 2.5xUNL , alkaline phosphatase liver fraction must ≤ 2.5xUNL . albumin ≥ 2.5 g/dL History DVT coagulation disturbance Need treatment oral anticoagulant LMW heparin Clinical resistance taxanes define progression therapy within 6 month end adjuvant treatment Known prior hypersensitivity taxanes drug contain chemophor , thalidomide ( analogue ) Preexisting peripheral neuropathy &gt; grade 1 Concomitant treatment non steroid antiinflammatory agent ( NSAIA ) , high dose steroid immunosuppressant Concomitant hormonal treatment ( include antiandrogenic ) Radiotherapy involve &gt; 30 % active bone marrow Radiotherapy ≤ 4 week prior enrolment Other chemotherapy treatment ≤ 4 week prior enrolment , least 6 week nitrosoureas mitomycin C , investigational drug Symptomatic brain metastasis Active infection Gastrointestinal abnormality , inability take oral medication , condition affect absorption Impaired cardiac function include follow : History cardiac disease , myocardial infarction , year prior enrollment clinical trial , symptomatic/uncontrolled angina pectoris , congestive heart failure uncontrolled cardiac ischemia , arrhythmia , abnormal leave ventricular ejection fraction , uncontrolled arterial hypertension . Major surgery two week prior enter clinical trial Concurrent treatment anticancer therapy History another neoplastic disease ( except basal cell carcinoma skin uterine cervix carcinoma situ adequately treat ) , unless remission ≥ 5 year Patient unable comply study protocol owe psychological , social geographical reason Pregnant lactate woman Men woman childbearing potential use effective method contraception Participation another clinical trial treatment investigational product within 30 day prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>